KeystoneBio | Automated Scientific and Market Intelligence

KeystoneBio

Benefits

Specifications

How-to

Learn More

AutomatedScientific + MarketIntelligence

Benefits

Put your discoveries on the path to value creation, without data overload

What patients need and the industry wants.

Understand the path to validation

Understand which data readouts have proven value for similar programs. Discern publicly available validating data points at the time of a BD deal. Track patterns in pharma dealmaking over time.

Estimate short and long term program value

Understand deals in your category including specific terms. Discern publicly available validating data points. Estimate peak revenue potential by identifying where you fit in the patient journey and potential share. Understand deal outcomes at each stage of development.

Analyze the right source data

Ensure you have deep understanding of the right market-driving data points in your category, across public, paywalled, and proprietary sources.

Prompt data directly

Generate precise, visually compelling reports that illustrate where you fit in the landscape and how you are differentiated.

A sample of our data sources

Benefits

Always adding

disease areas

Our algorithms perform at 95-100% accuracy based on human expert benchmarks. We don’t release new disease area capabilities until we’re certain of accuracy

Current Focus

Metabolic

Disorders affecting the body’s ability to convert food into energy, such as diabetes and obesity, which are rising globally and linked to multiple chronic conditions.

Next Up

Neurology

Conditions of the brain and nervous system, including Alzheimer’s, Parkinson’s, and epilepsy, where patient need is high and therapeutic innovation remains a major unmet opportunity.

Coming Soon

Inflammation & Immunology

Diseases driven by immune system dysregulation—like rheumatoid arthritis, lupus, and IBD—offering strong pipelines for innovation amid increasing autoimmune prevalence.

Coming Soon

Oncology

Encompasses the study and treatment of cancers, an evolving field with high clinical demand and significant attention due to its potential for breakthrough therapies.

About

We’re building AI market research agents that can automate complex value assessments, identify deal opportunities, pinpoint the right data benchmarks, and highlight key tradeoffs.

Connect with us

Be first in line when KeystoneBio launches, and receive updates as we build the better way to aim your drug development.

Request access

2025

KeystoneBio

Join the waitlist

Benefits

Specifications

How-to

Learn More

AutomatedScientific + MarketIntelligence

Benefits

Put your discoveries on

the path to business value, without data overload

What patients need and the industry wants.

Understand the path to validation

Understand which data readouts have proven value for similar programs. Discern publicly available validating data points at the time of a BD deal. Track patterns in pharma dealmaking over time.

Estimate short and long term program value

Analyze the right source data

Ensure you have deep understanding of the right market-driving data points in your category, across public, paywalled, and proprietary sources.

Prompt data directly

Generate precise, visually compelling reports that illustrate where you fit in the landscape and how you are differentiated.

A sample of our data sources

Benefits

Always adding disease areas

Our algorithms perform at 95-100% accuracy based on human expert benchmarks. We don’t release new disease area capabilities until we’re certain of accuracy

Current Focus

Metabolic

Disorders affecting the body’s ability to convert food into energy, such as diabetes and obesity, which are rising globally and linked to multiple chronic conditions.

Next Up

Neurology

Conditions of the brain and nervous system, including Alzheimer’s, Parkinson’s, and epilepsy, where patient need is high and therapeutic innovation remains a major unmet opportunity.

Coming Soon

Inflammation & Immunology

Diseases driven by immune system dysregulation—like rheumatoid arthritis, lupus, and IBD—offering strong pipelines for innovation amid increasing autoimmune prevalence.

Coming Soon

Oncology

Encompasses the study and treatment of cancers, an evolving field with high clinical demand and significant attention due to its potential for breakthrough therapies.

About

We’re building AI market research agents that can automate complex value assessments, identify deal opportunities, pinpoint the right data benchmarks, and highlight key tradeoffs.

Connect with us

Be first in line when KeystoneBio launches, and receive updates as we build the better way to aim your drug development.

Request access

For biotechs

For investors

For pharma

2025

For biotechs

For investors

For pharma

AutomatedScientific + MarketIntelligence

Benefits

Put your discoveries on

the path to business value, without data overload

What patients need and the industry wants.

Understand the path to validation

Understand which data readouts have proven value for similar programs. Discern publicly available validating data points at the time of a BD deal. Track patterns in pharma dealmaking over time.

Estimate short and long term program value

Estimate peak revenue potential with a guided market share analysis. Understand deal outcomes at each stage of development.

Analyze the right source data

Ensure you have deep understanding of the right market-driving data points in your category, across public, paywalled, and proprietary sources.

Prompt data directly

Generate precise, visually compelling reports that illustrate where you fit in the landscape and how you are differentiated.

A sample of our data sources

Benefits

Always adding disease areas

Our algorithms perform at 95-100% accuracy based on human expert benchmarks. We don’t release new disease area capabilities until we’re certain of accuracy

Current Focus

Metabolic

Disorders affecting the body’s ability to convert food into energy, such as diabetes and obesity, which are rising globally and linked to multiple chronic conditions.

Next Up

Neurology

Conditions of the brain and nervous system, including Alzheimer’s, Parkinson’s, and epilepsy, where patient need is high and therapeutic innovation remains a major unmet opportunity.

Coming Soon

Inflammation & Immunology

Diseases driven by immune system dysregulation—like rheumatoid arthritis, lupus, and IBD—offering strong pipelines for innovation amid increasing autoimmune prevalence.

Coming Soon

Oncology

Encompasses the study and treatment of cancers, an evolving field with high clinical demand and significant attention due to its potential for breakthrough therapies.

About

We’re building AI market research agents that can automate complex value assessments, identify deal opportunities, pinpoint the right data benchmarks, and highlight key tradeoffs.

Connect with us

Be first in line when KeystoneBio launches, and receive updates as we build the better way to aim your drug development.

Request access

For biotechs

For investors

For pharma

2025